A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics

Journal of Hospital Infection

Volumn 70, Issue 2, 2008, Pages 142-147

  Garey, K W ^a,b   Dao Tran, T K ^b   Jiang, Z D ^c   Price, M P ^b   Gentry, L O ^b   DuPont, H L ^b,c,d  

^a UNIVERSITY OF HOUSTON   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Prevention cohort; Risk index

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; AGING; ALGORITHM; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; CLOSTRIDIUM DIFFICILE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HIGH RISK POPULATION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; ROC CURVE; SCORING SYSTEM; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS; TEXAS;

EID: 50849139510     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2008.06.026     Document Type: Article

References (24)

1. Archibald L.K., Banerjee S.N., and Jarvis W.R. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 189 (2004) 1585-1589
2. Aslam S., Hamill R.J., and Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 5 (2005) 549-557
3. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
4. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New Eng J Med 353 (2005) 2433-2441
5. Manabe Y.C., Vinetz J.M., Moore R.D., Merz C., Charache P., and Bartlett J.G. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 123 (1995) 835-840
6. Fekety R., and Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. J Am Med Assoc 269 (1993) 71-75
7. Gerding D.N. Disease associated with Clostridium difficile infection. Ann Intern Med 110 (1989) 255-257
8. Kelly C.P., Pothoulakis C., and LaMont J.T. Clostridium difficile colitis. N Engl J Med 330 (1994) 257-262
9. Dubberke E.R., Reske K.A., Yan Y., Olsen M.A., McDonald L.C., and Fraser V.J. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 45 (2007) 1543-1549
10. Garey K.W., Graham G., Gerard L., et al. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother 40 (2006) 1030-1034
11. Lawrence S.J., Puzniak L.A., Shadel B.N., Gillespie K.N., Kollef M.H., and Mundy L.M. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 28 (2007) 123-130
12. Gerding D.N., Muto C.A., and Owens Jr. R.C. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 46 Suppl 1 (2008) S43-S49
13. Tan E.T., Robertson C.A., Brynildsen S., Bresnitz E., Tan C., and McDonald C. Clostridium difficile-associated disease in New Jersey hospitals, 2000-2004. Emerg Infect Dis 13 (2007) 498-500
14. Chandler R.E., Hedberg K., and Cieslak P.R. Clostridium difficile-associated disease in Oregon: increasing incidence and hospital-level risk factors. Infect Control Hosp Epidemiol 28 (2007) 116-122
15. Barbut F., Depitre C., Delmee M., Corthier G., and Petit J.C. Comparison of enterotoxin production, cytotoxin production, serogrouping, and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients. J Clin Microbiol 31 (1993) 740-742
16. Blossom D.B., and McDonald L.C. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 45 (2007) 222-227
17. McDonald L.C., Coignard B., Dubberke E., Song X., Horan T., and Kutty P.K. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28 (2007) 140-145
18. Hecker M.T., Aron D.C., Patel N.P., Lehmann M.K., and Donskey C.J. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 163 (2003) 972-978
19. Pulcini C., Cua E., Lieutier F., Landraud L., Dellamonica P., and Roger P.M. Antibiotic misuse: a prospective clinical audit in a French university hospital. Eur J Clin Microbiol Infect Dis 26 (2007) 277-280
20. Vaccheri A., Silvani M.C., Bersaglia L., et al. A 3 year survey on the use of antibacterial agents in five Italian hospitals. J Antimicrob Chemother 61 (2008) 953-958
21. Owens Jr. R.C., Donskey C.J., Gaynes R.P., Loo V.G., and Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46 Suppl 1 (2008) S19-S31
22. Jiang Z.D., DuPont H.L., Garey K., et al. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol 101 (2006) 1112-1116
23. Jiang Z.D., DuPont H.L., Garey K.W., et al. Association between serum IgG antibody to C. difficile toxin A and polymorphism of the interleukin-8 gene. Clin Gastroenterol Hepatol 5 (2007) 309-314
24. Kyne L., Warny M., Qamar A., and Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000) 390-397